IP Library Granted Patent US 11,596,614
Granted Patent B2
US 11,596,614 · App. 17/221,784 · Granted Mar 7, 2023

Treatment of intrahepatic cholestatic diseases

Inventors: Pol Boudes (Pennington, NJ); Charles A. McWherter (Oakland, CA)
Assignee: CymaBay Therapeutics, Inc.
A61K31/192A61K9/0053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,596,614
App. No.
17/221,784
Granted
Mar 7, 2023
Kind
B2
Abstract

Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.

Claims (16)

1. A method of treating an intrahepatic cholestatic disease by administering seladelpar or a salt thereof, where the daily dose of seladelpar or a salt thereof is 5 mg, when the dose is calculated as seladelpar.

2. The method of claim 1 where the seladelpar or a salt thereof is seladelpar L-lysine dihydrate salt.

3. The method of claim 1 where the seladelpar or a salt thereof is administered orally.

4. The method of claim 2 where the seladelpar L-lysine dihydrate salt is administered orally.

5. The method of claim 1 where the seladelpar or a salt thereof is administered once/day.

6. The method of claim 2 where the seladelpar L-lysine dihydrate salt is administered once/day.

7. The method of claim 3 where the seladelpar or a salt thereof is administered once/day.

8. The method of claim 4 where the seladelpar L-lysine dihydrate salt is administered once/day.

9. A method of treating an intrahepatic cholestatic disease by administering seladelpar or a salt thereof, where the daily dose of seladelpar or a salt thereof is 10 mg, when the dose is calculated as seladelpar.

10. The method of claim 9 where the seladelpar or a salt thereof is seladelpar L-lysine dihydrate salt.

11. The method of claim 9 where the seladelpar or a salt thereof is administered orally.

12. The method of claim 10 where the seladelpar L-lysine dihydrate salt is administered orally.

13. The method of claim 9 where the seladelpar or a salt thereof is administered once/day.

14. The method of claim 10 where the seladelpar L-lysine dihydrate salt is administered once/day.

15. The method of claim 11 where the seladelpar or a salt thereof is administered once/day.

16. The method of claim 12 where the seladelpar L-lysine dihydrate salt is administered once/day.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Oct 3, 2024
From: ABW CYCLOPS SPV LP
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 069833/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2024
From: BOUDES, POL; MCWHERTER, CHARLES A.
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 068243/0138 →
Continuity (9)
Continuation 17024971 · Sep 18, 2020
Continuation 16597313 · Oct 9, 2019
Continuation 16367660 · Mar 28, 2019
Continuation 15496875 · Apr 25, 2017
Continuation In Part 15271460 · Sep 21, 2016
Continuation 14663027 · Mar 19, 2015
Provisional Application 62343688 · May 31, 2016
Provisional Application 61968037 · Mar 20, 2014
Related Publication 20210220305A1 · Jul 22, 2021